
    
      To compare the efficacy and safety of ART-123 (low and high dose) to placebo on sensory
      symptoms of oxaliplatin-induced peripheral neuropathy (OIPN) in patients with unresectable
      metastatic colorectal cancer who receive oxaliplatin-containing chemotherapy
    
  